Kennedy Capital Management LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 64,846 shares of the medical equipment provider's stock after buying an additional 7,457 shares during the period. Kennedy Capital Management LLC's holdings in Hologic were worth $4,675,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Hologic in the 4th quarter valued at about $133,414,000. Boston Partners lifted its stake in Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. Invesco Ltd. grew its holdings in Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Hologic during the 4th quarter worth $27,007,000. Hedge funds and other institutional investors own 94.73% of the company's stock.
Hologic Stock Performance
HOLX traded down $1.36 during trading on Wednesday, hitting $56.50. The stock had a trading volume of 3,256,993 shares, compared to its average volume of 1,929,097. Hologic, Inc. has a twelve month low of $56.06 and a twelve month high of $84.67. The firm has a market capitalization of $12.68 billion, a P/E ratio of 17.82, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company's 50-day moving average price is $61.87 and its 200 day moving average price is $71.15.
Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, William Blair restated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic has a consensus rating of "Hold" and a consensus price target of $84.62.
Check Out Our Latest Stock Report on Hologic
Hologic Company Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Articles
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
